50 Participants Needed

Cognitive Behavioral Therapy for ARFID

RS
BP
Overseen ByBlythe Peterson, BS
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Massachusetts General Hospital
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 4 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

Randomized controlled trial of an exposure-based behavioral treatment (CBT) in adults with functional dyspepsia who meet criteria for avoidant/restrictive food intake disorder (ARFID) with weight loss.

Do I have to stop taking my current medications for this trial?

The trial does not specify that you must stop taking your current medications, but you need to be on a stable dose for 30 days if you are on any medication.

What data supports the idea that Cognitive Behavioral Therapy for ARFID is an effective treatment?

The available research does not provide specific data on the effectiveness of Cognitive Behavioral Therapy (CBT) for ARFID. Instead, it focuses on the use of CBT and Acceptance and Commitment Therapy (ACT) for depression. These studies suggest that both CBT and ACT are effective for treating depression, with some evidence indicating that CBT might outperform ACT. However, there is no direct evidence in the provided research about CBT's effectiveness for ARFID specifically.12345

What safety data exists for Cognitive Behavioral Therapy and related therapies?

The provided research does not directly address safety data for Cognitive Behavioral Therapy (CBT) or its related therapies like MBCT, DBT, or ACT. However, it does suggest that these therapies are being studied for their feasibility, acceptability, and clinical outcomes in various conditions such as borderline personality disorder, generalized anxiety disorder, and PTSD. This implies that these therapies are generally considered safe enough to be tested in clinical settings, but specific safety data is not detailed in the abstracts provided.678910

Is Cognitive Behavioral Therapy a promising treatment for ARFID?

Yes, Cognitive Behavioral Therapy (CBT) is a promising treatment. It includes approaches like Acceptance and Commitment Therapy (ACT), which has shown effectiveness in improving mental health conditions like anxiety and depression. These therapies help people manage their thoughts and emotions better, leading to improved quality of life.18101112

Research Team

HB

Helen Burton Murray, PhD

Principal Investigator

Massachusetts General Hospital

Eligibility Criteria

This trial is for adults with functional dyspepsia and ARFID, who've lost weight since the onset of FD. They must be stable enough for outpatient care, have not had CBT for FD or ARFID before, can use a computer with webcam, haven't changed medications recently, speak English fluently, and donโ€™t have certain medical conditions like psychosis or recent surgeries.

Inclusion Criteria

Negative upper endoscopy or upper radiographic GI series to rule out structural/organic cause for FD
Computer/internet webcam access
I have been diagnosed with a type of indigestion that gets worse after eating.
See 6 more

Exclusion Criteria

Inability to provide informed consent
Current enteral or parenteral feeding
Use of narcotic analgesics greater than three days per week
See 12 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive cognitive behavioral therapy for functional dyspepsia with avoidant restrictive food intake disorder, consisting of eight 1-hour sessions delivered weekly via a secure video platform

8 weeks
8 visits (virtual)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Cognitive Behavioral Therapy
Trial Overview The study tests an exposure-based cognitive behavioral therapy (CBT) specifically designed to treat avoidant/restrictive food intake in individuals suffering from functional dyspepsia. Participants are randomly assigned to receive this treatment to see if it helps improve their condition.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Cognitive Behavioral TherapyExperimental Treatment1 Intervention
Subjects will receive cognitive behavioral therapy for functional dyspepsia with avoidant restrictive food intake disorder.
Group II: Usual CareActive Control1 Intervention
In the usual care condition, participants will be allowed to continue with treatment they are already receiving at the time of randomization, and we will collect detailed data on the nature of these interventions. Participants will be allowed to pursue non study treatments in this condition.

Cognitive Behavioral Therapy is already approved in European Union, United States, Canada for the following indications:

๐Ÿ‡ช๐Ÿ‡บ
Approved in European Union as Cognitive Behavioral Therapy for:
  • Anxiety disorders
  • Depressive disorders
  • Eating disorders
  • Post-traumatic stress disorder (PTSD)
  • Obsessive-compulsive disorder (OCD)
๐Ÿ‡บ๐Ÿ‡ธ
Approved in United States as Cognitive Behavioral Therapy for:
  • Anxiety disorders
  • Depressive disorders
  • Eating disorders
  • Post-traumatic stress disorder (PTSD)
  • Obsessive-compulsive disorder (OCD)
  • Substance use disorders
๐Ÿ‡จ๐Ÿ‡ฆ
Approved in Canada as Cognitive Behavioral Therapy for:
  • Anxiety disorders
  • Depressive disorders
  • Eating disorders
  • Post-traumatic stress disorder (PTSD)
  • Obsessive-compulsive disorder (OCD)

Find a Clinic Near You

Who Is Running the Clinical Trial?

Massachusetts General Hospital

Lead Sponsor

Trials
3,066
Recruited
13,430,000+

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator

Trials
2,513
Recruited
4,366,000+

Findings from Research

Acceptance and Commitment Therapy (ACT) showed significant improvements in global mental health, depression, cognitive fusion, and values in complex clients treated by both psychologists and non-psychologists in a National Health Service setting.
The positive effects of ACT were partially maintained at a 3-month follow-up, indicating its potential long-term benefits, and outcomes were similar regardless of the therapist's professional background.
Development and Evaluation of Acceptance and Commitment Therapy Delivered by Psychologists and Non-Psychologists in an NHS Community Adult Mental Health Service: a Preliminary Analysis.Richardson, T., Bell, L., Bolderston, H., et al.[2018]
A randomized controlled trial with 82 patients showed that both Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) significantly reduced depressive symptoms and improved quality of life after 12 months, with no significant difference in effectiveness between the two therapies.
Both therapies appear to work by changing dysfunctional attitudes and promoting decentering, while experiential avoidance was specifically linked to treatment effects in ACT, suggesting different mechanisms of action despite similar outcomes.
One year follow-up and mediation in cognitive behavioral therapy and acceptance and commitment therapy for adult depression.A-Tjak, JGL., Morina, N., Topper, M., et al.[2021]
Acceptance and Commitment Therapy (ACT) is an effective treatment for Major Depressive Disorder (MDD), utilizing mindfulness and acceptance strategies to enhance psychological flexibility, which is crucial for behavior change.
ACT can be delivered in various formats, including individual, group, or self-help options, and has shown empirical support for its efficacy in improving depression outcomes through its core processes.
Acceptance and Commitment Therapy for Major Depressive Disorder: Insights into a New Generation of Face-to-Face Treatment and Digital Self-Help Approaches.Apolinรกrio-Hagen, J., Drรผge, M., Hennemann, S., et al.[2021]

References

Development and Evaluation of Acceptance and Commitment Therapy Delivered by Psychologists and Non-Psychologists in an NHS Community Adult Mental Health Service: a Preliminary Analysis. [2018]
One year follow-up and mediation in cognitive behavioral therapy and acceptance and commitment therapy for adult depression. [2021]
Acceptance and Commitment Therapy for Major Depressive Disorder: Insights into a New Generation of Face-to-Face Treatment and Digital Self-Help Approaches. [2021]
A Randomized Controlled Trial in Routine Clinical Practice Comparing Acceptance and Commitment Therapy with Cognitive Behavioral Therapy for the Treatment of Major Depressive Disorder. [2019]
Clinical errors in cognitive-behavior therapy. [2018]
A feasibility study of mindfulness-based cognitive therapy for individuals with borderline personality disorder. [2018]
A pilot study of group mindfulness-based cognitive therapy (MBCT) for combat veterans with posttraumatic stress disorder (PTSD). [2022]
Efficacy of an acceptance-based group behavioral therapy for generalized anxiety disorder. [2022]
[Borderline personality disorder and non-suicidal self-injury: the role of mindfulness training in risk reduction]. [2023]
Effect of acceptance-based behavior therapy on severity of symptoms, worry and quality of life in women with generalized anxiety disorder. [2021]
Comparing the effectiveness of acceptance-based behavior therapy and applied relaxation on acceptance of internal experiences, engagement in valued actions and quality of life in generalized anxiety disorder. [2022]
12.United Statespubmed.ncbi.nlm.nih.gov
An Acceptance-Based Behavioral Therapy for Individuals with Generalized Anxiety Disorder. [2020]